Sanofi Selects Recursion Immunology Drug Candidate for Development

Sanofi has optioned the first development candidate from its research collaboration with Recursion, adding it to its development pipeline. The potential first-in-class oral small molecule, developed using AI-enabled design, targets a challenging pair of targets implicated in inflammatory disease. Phase 1 trials are expected in 2027, with Sanofi funding and leading further development and commercialization. The option triggered a $10 million milestone payment, bringing total upfront and milestone payments under the collaboration to $144 million. Recursion remains eligible for more than $300 million in additional program milestones, with average low-double-digit royalties on net sales if successfully commercialized. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 202610150845PRIMZONEFULLFEED9846526) on October 15, 2026,